CogniPrin and FlexiPrin

$6.57 million judgment (partially suspended) / 20-year ban on direct response marketing of food, dietary supplements, or drugs for which a health benefit is claimed / Banned from making claims related to pain relief, cartilage rebuilding, cognitive decline, memory improvement, and disease unless substantiated by competent and reliable scientific evidence that is sufficient in quality and quantity based on standards accepted by experts in the relevant disease, condition, or function to which the representation relates when considered in light of the entire body of relevant and reliable evidence / Such testing shall be randomized, double-blind, and placebo-controlled and conducted by researchers qualified to conduct such testing/ Prohibited from misrepresenting any tests or studies, or that a product is clinically or scientifically proven to reduce pain or improve memory or cognition or that the benefits are scientifically proven / Prohibiting from misrepresenting endorsements.